Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Waldenstrom Macroglobulinemia 1Rectal Neoplasms 1Paraproteinemias 1Neoplasms 1

Interventions

Fluorouracil 155Oxaliplatin 133Leucovorin 124Capecitabine 90Irinotecan 88Radiotherapy 63Bevacizumab 61Cetuximab 38Folfox protocol 25Panitumumab 21Neoadjuvant Therapy 21Surgical Procedures, Operative 19Chemotherapy, Adjuvant 15Radiation 13Floxuridine 13Erlotinib Hydrochloride 13Early Intervention, Educational 13IFL protocol 11Drug Therapy 11Proctectomy 10Magnetic Resonance Spectroscopy 10Counseling 10Surveys and Questionnaires 8Sorafenib 8Psychiatric Rehabilitation 8Gene Expression Profiling 8Radiotherapy, Intensity-Modulated 7Immunohistochemistry 7Gemcitabine 7Celecoxib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Rectal Neoplasms × Rifaximin × Clear all
NCT01345175 2024-05-14

Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer

Memorial Sloan Kettering Cancer Center

Phase 3 Completed
69 enrolled 9 charts
Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡